Paper Details
- Home
- Paper Details
Original Abstract of the Article :
Since metoclopramide was first described (in 1964) there have been several attempts to develop compounds which retained gastrointestinal prokinetic activity (via 5-HT(4) receptor activation) but without the limiting side effects associated with dopamine D(2) receptor antagonism. Early compounds (mos...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://doi.org/10.1111/j.1365-2982.2009.01425.x
データ提供:米国国立医学図書館(NLM)
5-HT Receptor Pharmacology: A Journey Through the Brain
The 5-HT receptors are a family of proteins that play a crucial role in regulating various bodily functions, like a complex network of pathways guiding a caravan through the desert. This research explores the development of drugs targeting 5-HT receptors, specifically focusing on the 5-HT(4) receptor, which is involved in gastrointestinal motility.
The development of 5-HT(4) receptor agonists has been a challenging process, like navigating a treacherous desert landscape. Early drugs were often hampered by non-selectivity, leading to unwanted side effects. However, recent advancements have led to the development of more selective and potent agonists, such as prucalopride, which has shown promise in treating chronic constipation.
Unlocking the Potential
This research highlights the significant progress made in understanding the pharmacology of 5-HT receptors. It's like uncovering hidden treasures in the desert - new knowledge that can lead to better treatments for various conditions.
A New Era of Treatments?
The development of selective 5-HT(4) receptor agonists could represent a new era in the treatment of gastrointestinal disorders. It's like finding a new oasis in the desert - a source of hope for patients struggling with these conditions.
Dr.Camel's Conclusion
This research showcases the ongoing journey of drug discovery and the importance of understanding the intricate workings of the human body. The development of selective 5-HT(4) receptor agonists holds great promise for treating gastrointestinal disorders and improving the lives of patients.
Date :
- Date Completed 2010-01-25
- Date Revised 2022-03-31
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.